Actively Recruiting
Phase III Study of Zanubrutinib With or Without Sonrotoclax for Untreated Older Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Led by Alliance for Clinical Trials in Oncology · Updated on 2026-11-03
466
Participants Needed
261
Research Sites
521 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of adding sonrotoclax to zanubrutinib compared to zanubrutinib alone in treating patients with untreated chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. Sonrotoclax is a BCL-2 inhibitor that may stop cancer cell growth by blocking a protein needed for their survival, while zanubrutinib is a kinase inhibitor targeting a protein present at abnormal levels in certain B-cell cancers. This phase III trial aims to compare progression-free survival and other outcomes between these therapies. Participants are randomly assigned to receive either zanubrutinib alone or zanubrutinib combined with sonrotoclax. Zanubrutinib is given orally twice daily every 28-day cycle. In the combination group, sonrotoclax is added once daily from cycle 4. After 14 cycles, patients with undetectable minimal residual disease MRD may stop therapy or continue based on their response, with some undergoing additional therapy cycles. Throughout treatment, patients undergo CT scans, bone marrow aspirations, and blood sample collections. Participants will be followed during treatment and after completion for up to 10 years, with visits every 3 months for the first 3 years, then every 6 months. Assessments include disease progression, survival, MRD status, response rates, toxicity, and patient-reported symptoms. Safety monitoring focuses on infections, cardiovascular events, tumor lysis syndrome, bleeding, cytopenias, and secondary cancers. The total duration of participation can extend through long-term follow-up and additional monitoring as needed.
CONDITIONS
Brief Title
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Research Team
J
Jayke Giese
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here